Philippines vs United Arab Emirates: Percentage of bloodstream infection due to Escherichia coli resistant
Philippines
43.9%
in 2022
United Arab Emirates
52.4%
in 2022
Philippines rank
21st
United Arab Emirates rank
19th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Philippines
- United Arab Emirates
How they compare
United Arab Emirates currently reports 52.4% against 43.9% in Philippines, a difference of 8.5%.
That makes United Arab Emirates's figure about 1.2 times Philippines's.
Across all 6 years both countries report, United Arab Emirates has been ahead every year.
Philippines ranks 21st and United Arab Emirates ranks 19th of 50 countries.
United Arab Emirates has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Philippines | United Arab Emirates | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 38.5% | 47.5% | 9.0% | United Arab Emirates |
| 2020s | 41.2% | 52.7% | 11.5% | United Arab Emirates |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Philippines or United Arab Emirates?
- United Arab Emirates, at 52.4% against 43.9% in Philippines as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Philippines and United Arab Emirates?
- 8.5%, with United Arab Emirates ahead.
- How many years of comparable data are there for Philippines and United Arab Emirates?
- 6 years are reported by both, from 2017 to 2022.
- How do Philippines and United Arab Emirates rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Philippines ranks 21st and United Arab Emirates ranks 19th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.